Global Blood Therapeutics, Inc.
Azaindole compounds as histone methyltransferase inhibitors
Last updated:
Abstract:
The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Status:
Grant
Type:
Utility
Filling date:
7 Jun 2018
Issue date:
7 Sep 2021